New guidelines designed to address the alarming rise in bacterial resistance to antibiotics have been issued by The Sinus and Allergy Health Partnership, with representation from the U.S. Centers for Disease Control and Prevention and the Food and Drug Administration. The guidelines were developed to stem antibiotic resistance by helping health professionals to more accurately diagnose acute bacterial rhinosinusitis, reduce the use of antibiotics for non-bacterial infections and recommend the use of the most effective antibiotics when rhinosinusitis is likely.
New guidelines designed to address the alarming rise in bacterial resistance to antibiotics have been issued by The Sinus and Allergy Health Partnership, with representation from the U.S. Centers for Disease Control and Prevention and the Food and Drug Administration. The guidelines were developed to stem antibiotic resistance by helping health professionals to more accurately diagnose acute bacterial rhinosinusitis, reduce the use of antibiotics for non-bacterial infections and recommend the use of the most effective antibiotics when rhinosinusitis is likely.
The new guidelines are part of a national effort aimed at educating health care practitioners and patients about curbing antibiotic resistance by reducing the overuse of antibiotics and improving antibiotic treatment when a bacterial infection is diagnosed. The guidelines analyze and rank 17 antibiotics commonly used to treat sinusitis according to their efficacy in fighting the bacteria that most often cause this condition.
"Bacterial resistance to antibiotics is a growing public health threat to the United States," said Richard Besser of the CDC's respiratory disease branch, one of the contributors to the new guidelines. "These guidelines are an important tool for physicians to begin to attack the problem of antibiotic resistance with more accurate diagnosis and appropriate antibiotic treatments. Just as important, we are working to educate the public about the personal and public health dangers that can result from the overuse and misuse of antibiotics for conditions like sinusitis." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.